CRAI

ANALYST NOTE: CRA INTERNATIONAL, INC. (CRAI) DATE: 2026-06-13 CURRENT PRICE: $138.70

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 5.0% (High)

Structural Assessment:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None Named

At this date, CRAI is not anchored to a named macro or secular thesis (e.g., "AI Infrastructure Build-out" or "Global M&A Super-Cycle"). The investment case is strictly tactical, driven by the quality of the immediate setup and the strength of the underlying business fundamentals. The conviction must be derived entirely from the operational execution and financial metrics reported by management, rather than a top-down thematic tailwind. The absence of a named thesis means the setup quality and fundamental evidence carry the full weight of the conviction stack.

3. Business Analysis

Company Profile: CRA International, Inc. is a leading global consulting firm specializing in economic, financial, and management consulting services. Headquartered in Boston, Massachusetts, the firm advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, while also guiding corporations through critical business strategy and performance issues.

Business Model & Operations: The company operates through two broad service areas:

• Litigation, Regulatory, and Financial Consulting: Providing expert witness testimony, economic analysis, and forensic accounting.
• Management Consulting: Covering strategy formulation, performance enhancement, valuation, and competitive intelligence.

Key Operational Metrics (as of Q1 FY2026):

• Revenue Growth: Revenue increased 10.5% year-over-year to $201.0 million (Source: E1, E9).
• Pipeline Health: The sales pipeline, average weekly project lead flow, and new project originations all set quarterly records with double-digit growth relative to Q1 2025 (Source: E2).
• Practice Performance: Four practices—Energy, Finance, Forensic Services, and Life Sciences—posted double-digit revenue growth. The Antitrust & Competition Economics practice reached a new high for quarterly revenue (Source: E4).
• Utilization & Headcount: Consultant utilization rose to 77% (up from 76% YoY), and headcount increased to 971 consultants (up from 947 YoY) (Source: E10).
• Contract Mix: Fixed-price projects increased to 18% of net revenues, up from 17% in the prior year, indicating a slight shift toward more predictable revenue streams (Source: E12).
• Geographic Diversification: Approximately 20% of net revenues were derived from outside the U.S. (Source: E11).
• Client Concentration: No single client accounts for more than 10% of revenues, ensuring a diversified client base across industries including technology, healthcare, energy, and financial services (Source: E24).

Financial Guidance & Liquidity: Management reaffirmed full-year financial guidance for fiscal 2026 (Source: E3). Liquidity remains robust; the company amended its Credit Agreement on May 4, 2026, increasing its revolving credit facility capacity by $50.0 million to $300.0 million (Source: E13). Management stated that current cash, cash equivalents, and operating cash flow are sufficient to meet working capital and capex requirements for at least the next 12 months (Source: E16).

4. Archetype and Conviction

Archetype: Growth Leader Rationale: CRAI fits the Growth Leader archetype based on the convergence of accelerating revenue (10.5% YoY), expanding headcount, and record-breaking pipeline metrics. The company is successfully scaling its workforce (971 consultants) while maintaining high utilization (77%), a hallmark of a firm in a growth phase rather than a cyclical recovery or defensive operator.

Valuation & Financial Spine: The financial spine indicates a forward consensus EPS of $8.24 for FY1 and $8.60 for FY2 (Source: E32). This implies a forward P/E ratio of approximately 16.8x based on the current price of $138.70. While not explicitly labeled as "deep value," the multiple appears reasonable for a firm delivering double-digit growth with a strong balance sheet and reaffirmed guidance.

Conviction Stack:

• Thesis Strength: Low (Tactical only, no macro tailwind).
• Evidence Quality: High. Multiple primary sources (earnings transcripts, 10-Q/10-K filings) confirm strong operational momentum, record pipeline, and disciplined capital management.
• Structural Quality: Neutral. The business fundamentals are strong, but the technical setup is currently undefined (context-only).
• Rerating Potential: Moderate. The combination of record pipeline, fixed-price mix expansion, and reaffirmed guidance provides a foundation for multiple expansion if the technical structure forms.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental: A significant miss on the reaffirmed full-year guidance or a contraction in the sales pipeline (e.g., failure to maintain double-digit growth in lead flow) would weaken the growth thesis.
• Operational: A decline in utilization below 75% or a failure to retain headcount would signal a slowdown in demand.

Strengtheners:

• Technical: A confirmed breakout above a defined resistance level with volume confirmation.
• Fundamental: Continued double-digit growth in the Energy and Life Sciences practices, or an increase in the fixed-price contract mix beyond 18%.
• M&A Activity: Sustained high levels of global M&A activity (currently $1.2T in Q1 2026) directly benefit the Antitrust and Finance practices.

Evidence Gaps:

• Margin Detail: While EBITDA is mentioned, specific margin expansion data (e.g., operating margin % vs. prior year) is not explicitly detailed in the provided evidence, though cost of services increased 20.4% against 10.5% revenue growth (Source: E14), which warrants monitoring for margin compression.
• Forward Guidance Specifics: While guidance is reaffirmed, the specific numerical targets for the full year are not provided in the evidence snippets.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Revenue up 10.5% YoY to $201M; Pipeline and lead flow set quarterly records; Reaffirmed full-year guidance; Revolving credit facility increased to $300M. Expected path: Management expects continued double-digit growth in pipeline and revenue; structural setup will likely form as price consolidates or breaks out from current levels. Expected horizon: 3 to 6 months for a structural setup to form and resolve.